Figma Inc. Class A Common Stock vs IDEXX Laboratories, Inc. — how do they compare? Figma Inc. Class A Common Stock trades at $21.26 (market cap $11.60B), while IDEXX Laboratories, Inc. trades at $532.96 (market cap $40.99B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.5× Figma Inc. Class A Common Stock's market cap, and IDEXX Laboratories, Inc. is more actively traded (445,410 versus 12,281,013). Which is the better fit depends on your goals — on Pluang, investors hold Figma Inc. Class A Common Stock for 0 Days and IDEXX Laboratories, Inc. for 47 Days on average.
| FIG | IDXX | |
|---|---|---|
Market Cap | $11.60B | $40.99B |
Volume | 12,281,013 | 445,410 |
Sector | Technology | Health |
52-Week High | $63.82 | $766.68 |
52-Week Low | $16.84 | $504.70 |
Typical Hold Time | 0 Days | 47 Days |
Enterprise Value | $10.00B | $41.89B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
IDEXX Laboratories (IDXX) trades at $529.01, up 0.97% with strong fundamental performance including 25.03% net income margin and consistent earnings beats. The stock shows neutral technical signals with support at $518 and resistance at $528. Recent acquisitions like CoVetAI and diagnostic platform expansions demonstrate strategic growth initiatives. Revenue grew from $3.9B in 2024 to $4.3B in 2025 with profit margins expanding to 24.61%.
Outlook remains positive with 56.5% analyst buy ratings and $665 consensus price target representing 25.7% upside. Key risks include FX headwinds and weaker U.S. vet visits, but strong recurring revenue and diagnostic innovation pipeline support long-term growth framework. The company's premium valuation (P/E 36.56) reflects market confidence in sustained profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Figma, Inc. is a US software company that operates a collaborative interface design and product development platform used by design and engineering teams to create, prototype, and build digital products.
Read more on FIG →Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →